Elmira Hassanzadeh1, Olutayo I Olubiyi1, Andriy Fedorov 1, Daniel I Glazer1, Clare M Tempany1, and Fiona M Fennessy1,2
1Brigham and Women's Hospital, Boston, MA, United States, 2Dana-Farber Cancer Institute, Boston, MA, United States
One of the challenges in prostate cancer (PCa) management is
the ability to differentiate aggressive tumors that require prompt treatment
from indolent tumors that can safely undergo active surveillance. To promote
global standardization and diminish variation in the acquisition,
interpretation, and reporting of prostate multi-parametric MRI (mpMRI) examinations, Prostate Imaging
Reporting and Data System (PI-RADS) has been introduced. The second
version of PI-RADS (PI-RADS v2) was released early in 2015, but requires
clinical validation. Here, we present the results of a study investigating the
performance of PI-RADS v2 compared to quantitative ADC (qADC) values in discriminate
high-grade from low-grade PCa.
